Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Radium Ra 223 dichloride in castration-resistant prostate cancer.

J Y Joung1, Y S Ha, I Y Kim

  • 1Section of Urologic Oncology and the Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea. kimiy@umdnj.edu.

Drugs of Today (Barcelona, Spain : 1998)
|August 27, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global transcriptome analysis identifies weight regain-induced activation of adaptive immune responses in white adipose tissue of mice.

International journal of obesity (2005)·2018
Same author

Applying reinforcing sutures to stapled colorectal anastomosis after low anterior resection for rectal cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2015
Same author

Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2015
Same author

Factors affecting the restaging accuracy of magnetic resonance imaging after preoperative chemoradiation in patients with rectal cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2015
Same author

Effect of high dietary sodium on bone turnover markers and urinary calcium excretion in Korean postmenopausal women with low bone mass.

European journal of clinical nutrition·2015
Same author

Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Radium Ra 223 dichloride improved survival in men with prostate cancer bone metastases. This alpha-particle therapy shows skeletal targeting and antitumor effects with low bone marrow toxicity.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Radium Ra 223 dichloride is an alpha-particle-emitting radioisotope.
  • It exhibits skeletal targeting and antitumor effects with low bone marrow toxicity in preclinical models.
  • Bone metastases are a common complication in castration-resistant prostate cancer (CRPC).

Purpose of the Study:

  • To evaluate the efficacy and safety of radium Ra 223 dichloride in patients with CRPC and bone metastases.

Main Methods:

  • A randomized, placebo-controlled phase III trial (ALSYMPCA) was conducted.
  • Patients received six cycles of radium Ra 223 dichloride (50 kBq/kg) at 4-week intervals.
  • Overall survival was the primary endpoint.
Keywords:
Bone metastasisCastration-resistant prostate cancerRadionuclide therapyRadium Ra 223 dichloride

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

Related Experiment Videos

Last Updated: May 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

Main Results:

  • Radium Ra 223 dichloride significantly improved median overall survival by 3.6 months compared to placebo.
  • The treatment demonstrated a favorable safety profile with limited bone marrow toxicity.
  • Antitumor effects and skeletal targeting were observed.

Conclusions:

  • Radium Ra 223 dichloride is a promising therapeutic option for managing bone metastases in CRPC patients.
  • It offers a survival benefit and manageable toxicity.
  • Further research may explore its role in earlier stages of prostate cancer.